Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol.
Petr JirasekAlexandr JuskuJana FrankovaMarketa UrbankovaDaniel DiabelkoFilip RuzickaBarbora PapouskovaKarin ChytilovaJiri VrbaJakub HavlasekKaterina LangovaJan StorchIva VobornaVilim SimanekJan VacekPublished in: Journal of periodontal research (2024)
Cannabidiol reduced inflammation and the growth of selected periodontal pathogenic bacteria. The clinical trial demonstrated a statistically significant improvement after CBD application. No adverse effects of CBD were reported by patients or observed upon clinical examination during the study. The results are a promising basis for a more comprehensive investigation of the application of non-psychotropic cannabinoids in dentistry.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- end stage renal disease
- oxidative stress
- phase ii
- newly diagnosed
- study protocol
- ejection fraction
- phase iii
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- radiation therapy
- mesenchymal stem cells
- patient reported outcomes
- adverse drug